

Implications of HSP 90 Q488H Polymorphism in Long QT Syndrome—A South Indian Study

Altaf Ali¹, Sameera F. Qureshi¹, Ananthapur Venkateshwari², Narsimhan Calambur³, Hygriv Rao⁴, Machinary Puthenpurayil Jayakrishnan⁵, Jayaprakash Shenthar⁶, Kumarasamy Thangaraj⁷ and Pratibha Nallari^{1*}

¹Department of Genetics, University College of Science, Osmania University, Hyderabad-500007, Telangana, India; ²Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Begumpet, Hyderabad-500016, Telangana, India; ³Care Hospital, Hyderabad, Telangana, India; ⁴Krishna Institute of Medical Sciences, 1-8-31/1, Minister Road, Secunderabad-500 003, Telangana, India; ⁵Institute of Maternal and Child Health, Calicut Medical College, Calicut 8, Kerala, India; ⁶Sri Jayadeva Institute of Cardiovascular Science and Research, Jayanagar 9th Block, Bannerghatta Road, Bangalore 560069, Karnataka, India; ⁷Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad 500 007, Telangana, India

Abstract

Background and objective: Long QT syndrome (LQTS) is a rare primary cardiac electrophysiological disorder with characteristic symptoms of syncope, tachyarrhythmia and torsades-de-pointes. It is the outcome of mutations in genes encoding ion channels that function as voltage regulators. Heat shock protein (HSP) 90 is a molecular chaperone that plays vital roles in a variety of cellular processes, one of which is folding of nascent polypeptide chains into their native forms. The main objective of this study was to screen for *HSP90* Q488H (C > G) polymorphism in patients with LQTS and identify its risk towards LQTS manifestation.

Methods: Allele-specific PCR was employed to genotype 49 LQTS patients, 71 first-degree relatives (FDRs) and 219 controls for the *HSP90* Q488H polymorphism. The genotypes were statistically evaluated to assess their association with the risk of LQTS. Further, bioinformatic analysis was performed to validate the statistical findings.

Results: Genotyping and statistical evaluation revealed a significant association of the CG genotype with LQTS, pointing towards a heterozygote disadvantage in the patients. The GG and CG genotypes showed a significant association with LQTS in the FDRs. Secondary pre-mRNA structure of the variant allele 'G' was found to be more stable than the wild-type structure.

Conclusions: Individuals harboring the heterozygous "CG" genotype are at increased risk for LQTS. In the FDRs, especially, the females harboring the "CG" and "GG" genotypes could transmit the risk allele to the future generation, giving rise to a disadvantage towards LQTS. It is imperative that all FDRs undergo carrier detection and/or prenatal diagnosis to prevent the recurrence of dominant-negative effect leading to sudden cardiac death events among the current and future generations.

Keywords: LQTS; HSP90; Q488H; AS-PCR; Syncope; SCD.

Introduction

The heat shock protein 90 (HSP90), an abundant ubiquitous molecular chaperone, plays an essential role in varied cellular processes, including cell cycle control and cell survival, as well as hormonal and other signaling pathways. It also plays a vital role in cell stress responses and maintains cellular homeostasis, promoting the correct maturation and activation of a number of key cellular proteins and protein complexes.¹ The highly conserved HSP90 family of proteins exists in all organisms, except for archaea, and is classified into five large subfamilies: the cytosolic HSP90s, the en-

Exploratory Research and Hypothesis in Medicine 2018 vol. 3 | 21–27

Abbreviations: CFTR, cystic fibrosis transmembrane conductance receptor; CI, confidence interval; ECG, electrocardiography; HSP, heat shock protein; FDR, first-degree relative; LQTS, long QT syndrome; OR, odds ratio; SD, standard deviation; SNP, single nucleotide polymorphism.

Received: March 18, 2017; Revised: November 11, 2017; Accepted: November 30, 2017

^{*}Correspondence to: Pratibha Nallari, Department of Genetics, University College of Science, Osmania University, Hyderabad-500007, Telangana, India. E-mail: pratibha.genetics@gmail.com

How to cite this article: Ali A, Qureshi SF, Venkateshwari A, Calambur N, Rao H, Jayakrishnan MP, Shenthar J, Thangaraj K, Nallari P. Implications of HSP 90 Q488H Polymorphism in Long QT Syndrome—A South Indian Study. *Exploratory Research and Hypothesis in Medicine* 2018;3(2):21–27. doi: 10.14218/ERHM.2017. 00004.



Fig. 1. *HSP90α* genotypes (Q488H). AS-PCR for Q488H polymorphism (900bp product size). Lanes: 1 and 2, CC;3 and 4, CG;5 and 6, GG;7, 250bp-marker. Abbreviation: HSP, heat shock protein.

doplasmic reticulum-localized Grp94, the mitochondrial TRAP1, the chloroplast HSP90, and the bacterial HtpG.¹

HSP90 has two major cytoplasmic isoforms, *HSP90a* (inducible form/major form) and *HSP90β* (constitutive form/minor form). Recent reports have suggested the existence of another isoform, *HSP90N*, associated with cellular transformation.² The genomic location of human *HSP90a* is at 14q32-33, of *HSP90β* is at 6p21 and of *HSP75* is at 16p13.3 respectively; all three are documented as functional proteins.^{2,3} Since earlier studies have reported the involvement of HSP90 in the folding of complex proteins such as cystic fibrosis transmembrane conductance receptor (CFTR), the current study aimed to identify the chaperone's role in the folding of ion channel proteins, which when mutated leads to LQTS. Hence, a missense polymorphism leading to an amino acid change in HSP90 was studied.

Methods

We enrolled 219 unrelated individuals from Osmania General Hospital (Hyderabad, Telangana State, India) as controls and 49 LQTS probands with 71 available family members in the study, after

Table 1. Epidemiological distribution of controls and LQTS cases

obtaining informed consent. The study was designed and carried out in accordance with the ethical guidelines set under the 1975 Helsinki Declaration and was approved by the Institutional Ethical Committee of Osmania University (Hyderabad, Telangana State, India). The participants were clinically evaluated based on a 12lead electrocardiography (ECG) read by the consultant cardiologists at CARE Hospitals (Nampally, Banjara Hills, Secunderabad, Telangana, India; Sri Jayadeva Institute of Cardiovascular Science and Research, Bangalore, Karnataka, India; and, Institute of Maternal and Child Health, Calicut Medical College, Kerala, India).

Peripheral blood (5 mL) samples were collected from all the participants and DNA was isolated following the standard protocol.⁴ Single nucleotide polymorphism (SNP) genotyping was performed by an amplifying refractory mutation system PCR. Two sets of reactions were set up for each sample, using a common primer (CF: TGGATAACTGTGAGGAGGCTAA) and one of the reverse primers (RC: CCTGTGATATAATAGATATGTTTC/RT: CCTGTGATATAATAGATATGTTTG) specific for the different alleles of the polymorphic locus.⁵ The PCR reaction was set up in an Eppendorf Master Cycler using the conditions of initial denaturation at 95 °C for 5m, denaturation at 95 °C for 30 s, annealing at 63.5 °C for 30 s, extension at 72 °C for 30 s and final extension at 72 °C for 5 m (Fig. 1).

The allelic and genotypic frequencies of the Q488H polymorphism were established. The online tool SNPStats (version 1.29; accessed on 25-08-2015) was used to estimate the odds risk at 95% confidence interval (CI), to test for association between various genotypic combinations and LQTS.⁶ Chi-square test for association of differentiation between the controls and the LQTS group was also carried out using the Sociostatistics online tool (version 4.0.30319; accessed on 25-08-2015).⁷

Insilico analysis was performed to understand the stability of the pre-mRNA molecules of the two variant sequences of $HSP90\alpha$ Q488H polymorphism. Secondary pre-mRNA structures were built as per the background algorithm in the Vienna webserver (version 2.4; accessed on 25-08-2015),⁸ which helped in identifying distinct

Variable	Controls, n (%)	LQTS, (%)	Fisher's <i>p</i> -value
aLQTS		9 (18.3)	
cLQTS	-	40 (81.7)	
Sex			
Male	100 (45.67)	21 (42.9)	0.7531
Female	119 (54.33)	28 (57.1)	
Sex ratio	0.84:1	0.75:1	
Guadana		aLQTS, 5	
Syncope	-	cLQTS, 26	
Consanguinity	-	12 (24.5)	
Deafness	-	4 (8.69)	
Variable	Controls (<i>n</i> = 219), mean ± SD		LQTS (<i>n</i> = 49), mean ± SD
Age in years			
Male	31.1 ± 8.26		19.23 ± 16.5

Abbreviations: LQTS, long QT syndrome; SD, standard deviation.

27.05 ± 10.08

29.08 ± 9.41

22.95 ± 18.4

21.3 ± 17.4

Female

Pooled

· · · ·			
Type of LQTS	Males, n (%)	Females, n (%)	Pooled, <i>n</i> (%)
cLQTS	17 (42.5)	23 (27.5)	40 (81.6)
aLQTS	4 (44.4)	5 (55.6)	9 (18.4)
	Col	nsanguinity, N = 49	
cLQTS	4 (40)	6 (60)	10 (21)
aLQTS	-	2 (100)	2 (4.3)
	Family histo	ory of sudden death, <i>N</i> = 49	
cLQTS	6 (50)	6 (50)	12 (26)
aLQTS	1 (50)	1 (50)	2 (4.3)
Type of LQTS	Males, mean ± SD (msec)	Females, mean ± SD (msec)	Pooled, mean ± SD (msec)
	Q	T interval <i>, N</i> = 49	
cLQTS	500 ± 36	478 ± 30	490 ± 34
aLQTS	517 ± 9.2	479 ± 76.7	494 ± 58

Table 2. Distribution of LQTS cases into subtypes based on clinical characteristics

Abbreviations: LQTS, long QT syndrome; SD, standard deviation.

energy changes for the respective alleles of the polymorphic locus. Prediction of the transcription factors binding to the variants was performed using the online tool Alibaba (version 2.0; accessed on 25-08-2015). The secondary protein structure of the HSP90a molecule was predicted using the PSIPRED online tool (version 4.01; accessed on 20-03-2016).⁹

Results

Table 1 represents the epidemiological data of the present study. It was observed that 9 out of the 49 patients were aLQTS cases (18.4%), with 5 of those being syncope positive (55.5%); meanwhile 26 (65%) of the 40 cLQTS (81.6%) cases were syncope positive. The 21 male cases (42.9%) had a mean age of 19.23 years (standard deviation (SD) = 16.5), whereas the 28 female cases (57.1%) had a mean age of 22.95 years (SD = 18.4), indicating early onset of LQTS in males compared to the females.

Twelve (24.5%) of the 49 LQTS cases revealed consanguinity with the majority, represented by female cases; this finding highlighted the presence of recessive alleles of LQTS genes in the general population. The cLQTS cases showed a pooled ECG value of 490 ± 34 ms compared to the aLQTS cases (494 ± 58 ms) (Table 2).

As seen from Table 3, the 'G' allele frequency was higher in the LQTS group (0.42), when compared to the FDRs (0.38) and the controls (0.26), significantly deviating from the Hardy-Weinberg equilibrium ($\chi^2 = 9.1$, p = 0.003 and $\chi^2 = 7.74$, p = 0.005 respectively). The "CG" genotype showed higher frequency in the FDRs (54.9%), when compared to the LQTS group (26.5%) and controls (10%). Similarly, the "GG" genotype showed higher frequency in the LQTS group (28.6%), when compared to the other two groups (controls: 21.5% and FDRs: 11.3%), significantly deviating from the Hardy-Weinberg equilibrium ($\chi^2 = 12.7$, p = 0.0018 and $\chi^2 =$ 11.06, p = 0.004 respectively). The higher frequency of the "CG" genotype in the FDRs and LQTS cases compared to the controls clearly highlights the risk posed by the heterozygous "CG" genotype in the disease etiopathogenesis. Likewise, the higher proportion of the 'G' alleles in the LQTS cases and FDRs compared to the controls could prove hazardous, leading to a poor prognosis.

Interesting results were obtained upon comparing FDRs against the controls in order to identify variations/deviations from the Hardy-Weinberg equilibrium. Due to the higher frequency of the "CG" genotype (54.9%) compared to the controls, a deviation of χ^2 =

CND	Construct	Controls $C(N = 210) = n(N)$	10TS D (N = 40) = 0	(0/1)		χ ² * (<i>p</i> -val	ue)
SNP	Genotype	Controls C (N = 219), n (%)	LQ13 P (N = 49), II (%)) FDR(N = 71), n(76)	C vs P	FDR vs P	C vs FDR
	СС	150 (68.5)	22 (44.9)	2 4 (33.8)			
<i>HSP90α</i> Q488H	CG	22 (10)	13 (26.5)	39 (54.9)	12.7* (0.0018)	11.06* (0.004)	65.04* (<0.00001)
	GG	47 (21.5)	14 (28.6)	8 (11.3)	(0.0010)	(0.004)	(\0.00001)
CND		Controls $(N = 420) = (f)$	IOTC(N = 0.0) = (f)	FDD(M = 1.42) = (f)		χ ² * (<i>p</i> -valu	ie)
SINP	Alleles	controls (N = 458), n (1)	LQ13 (N = 98), n(1)	FDR (/V = 142), // (I)	C vs P	FDR <i>vs</i> P	C vs FDR
	С	322 (0.74)	57 (0.58)	87 (0.62)	9.1**	0.23	7.74**
ΗΣΡ90α Q488H	G	116 (0.26)	41 (0.42)	55 (0.38)	(0.003)	(0.63)	(0.005)

Table 3. Genotype and allele frequency distribution of the HSP90 Q488H polymorphism

* χ^2 T = 5.991 at 2 degrees of freedom; ** χ^2 T = 3.84 at 1 degree of freedom. Abbreviations: FDR, first degree relative; HSP, heat shock protein; LQTS, long QT syndrome.

Explor Res Hypothesis Med

Table 4. Genotype distribution of the $HSP90\alpha$ Q488H polymorphism in controls, LQTS cases and FDRs

SNP	Model	Genotype	Controls	LQTS	Adjusted OR (95%CI)	p
		C/C	150	22	1.00	
	Codominant	C/G	22	13	4.25 (1.69–10.68)*	0.0055*
		G/G	47	14	2.23 (0.98–5.09)	
	Dominant	C/C	150	22	1.00	0.0020*
HSP 90α Q488H	Dominant	C/G-G/G	69	27	2.88 (1.43–5.82)*	0.0029
	Pocossivo	C/C-C/G	172	35	1.00	0.25
	Recessive	G/G	47	14	1.59 (0.73–3.44)	0.25
	Over-dominant	C/C-G/G	197	36	1.00	0.0088*
	Over-dominant	C/G	22	13	3.30 (1.39–7.88)*	0.0088
SNP	Model	Genotype	FDR's	Cases	Adjusted OR (95%CI)	p
		C/C	24	22	1.00	
	Codominant	C/G	39	13	0.46 (0.15–1.42)	0.021
		G/G	8	14	2.81 (0.67–11.83)	
	D	C/C	24	22	1.00	0.74
HSP 90α Q488H	Dominant	C/G-G/G	47	27	0.82 (0.30–2.28)	0.71
	Deservice	C/C-C/G	63	35	1.00	0.045*
	Recessive	G/G	8	14	4.54 (1.24–16.57)*	0.015*
	Over deminant	C/C-G/G .	32	36	1	0.010*
	Over-dominant	C/G0	39	13	0.31 (0.11–0.83)*	0.018
SNP	Model	Genotype	Controls	FDR's	Adjusted OR (95%CI)	p
SNP	Model	Genotype C/C	Controls	FDR's	Adjusted OR (95%CI) 1.00	p
SNP	Model Codominant	Genotype C/C C/G	Controls 150 22	FDR's 24 39	Adjusted OR (95%Cl) 1.00 11.77 (5.4–25.64)*	p <0.0001*
SNP	Model Codominant	Genotype C/C C/G G/G	Controls 150 22 47	FDR's 24 39 8	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02)	p <0.0001*
SNP	Model Codominant	Genotype C/C C/G G/G C/C	Controls 150 22 47 150	FDR's 24 39 8 24	Adjusted OR (95%Cl) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00	p <0.0001*
SNP HSP 90α Q488H	Model Codominant Dominant	Genotype C/C C/G G/G C/C C/C-G/G	Controls 150 22 47 150 69	FDR's 24 39 8 24 47	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)*	p <0.0001* <0.0001*
SNP HSP 90α Q488H	Model Codominant Dominant	Genotype C/C C/G G/G C/C C/C-G/G C/C-C/G	Controls 150 22 47 150 69 172	FDR's 24 39 8 24 47 63	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00	p <0.0001* <0.0001*
SNP HSP 90α Q488H	Model Codominant Dominant Recessive	Genotype C/C C/G G/G C/C C/C-C/G C/C-C/G G/G	Controls 150 22 47 150 69 172 47	FDR's 24 39 8 24 47 63 8	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13)	p <0.0001* <0.0001* 0.062
SNP HSP 90α Q488H	Model Codominant Dominant Recessive	Genotype C/C C/G G/G C/C C/C-G/G C/C-C/G G/G C/C-G/G	Controls 150 22 47 150 69 172 47 197	FDR's 24 39 8 24 47 63 8 32	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00	p <0.0001*
SNP HSP 90α Q488H	Model Codominant Dominant Recessive Over-dominant	Genotype C/C C/G G/G C/C C/C-G/G C/C-C/G G/G C/C-G/G C/C-G/G C/C-G/G	Controls 150 22 47 150 69 172 47 197 22	FDR's 24 39 8 24 47 63 8 32 39	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)*	p <0.0001* <0.0001* 0.062 <0.0001*
SNP HSP 90α Q488H	Model Codominant Dominant Recessive Over-dominant Allele	Genotype C/C C/G G/G C/C C/C-G/G C/C-C/G G/G C/C-G/G C/G C/C	Controls 150 22 47 150 69 172 47 197 22 LQTS	FDR's 24 39 8 24 47 63 8 32 39 Unad	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)* justed OR (95%CI)	p <0.0001*
SNP HSP 90α Q488H SNP	Model Codominant Dominant Recessive Over-dominant Allele C	Genotype C/C C/G G/G C/C-C/G G/G C/C-C/G G/G C/C-G/G C/G	Controls 150 22 47 150 69 172 47 197 22 LQTS 57	FDR's 24 39 8 24 47 63 8 32 39 Unad 1.00	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)* justed OR (95%CI)	p <0.0001*
SNP HSP 90α Q488H SNP HSP 90α Q488H	Model Codominant Dominant Recessive Over-dominant Allele C G G	Genotype C/C C/G G/G C/C C/G-G/G C/C-C/G G/G C/C-G/G C/G S22 116	Controls 150 22 47 150 69 172 47 197 22 LQTS 57 41	FDR's 24 39 8 24 47 63 8 32 39 Unad 1.00 1.9 (1	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)* justed OR (95%CI) .24–3.2)*	p <0.0001*
SNP HSP 90α Q488H SNP HSP 90α Q488H	Model Codominant Dominant Recessive Over-dominant Allele C G G	Genotype C/C C/G G/G C/C-C/G G/G C/C-C/G G/G C/C-G/G C/G Market S22 116	Controls 150 22 47 150 69 172 47 197 22 LQTS 57 41	FDR's 24 39 8 24 47 63 8 32 39 Unad 1.00 1.9 (1	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)* justed OR (95%CI) .24–3.2)*	p <0.0001*
SNP HSP 90α Q488H SNP HSP 90α Q488H SNP HSP 90α Q488H	Model Codominant Codominant Dominant Recessive Over-dominant C Allele G Allele Allele	Genotype C/C C/G G/G C/C C/G-G/G C/C-C/G G/G C/C-G/G C/G J22 116	Controls 150 22 47 150 69 172 47 197 22 LQTS 57 41	FDR's 24 39 8 24 47 63 8 32 39 Unad 1.00 1.9 (1	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)* justed OR (95%CI) justed OR (95%CI)	p <0.0001*
SNP HSP 90α Q488H SNP HSP 90α Q488H SNP HSP 90α Q488H HSP 90α Q488H	Model Codominant Codominant Dominant Recessive Over-dominant C C G Allele C Allele C C C C C C C C C C C C C C C C C	Genotype C/C C/G G/G C/C-C/G G/G C/C-C/G G/G C/C-G/G C/G	Controls 150 22 47 150 69 172 47 197 22 LQTS 57 41 Cases 57	FDR's 24 39 8 24 47 63 8 32 39 Unad 1.00 1.9 (1 1.00	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)* justed OR (95%CI) .24–3.2)* justed OR (95%CI) 1.14 (0.65–1.9)	p <0.0001*
SNP HSP 90α Q488H SNP HSP 90α Q488H SNP HSP 90α Q488H HSP 90α Q488H	Model Codominant Dominant Dominant Recessive Over-dominant C G Allele C G C G G C G G	Genotype C/C C/G G/G C/C-G/G C/C-C/G G/G C/C-G/G C/G J22 116 FDR's 87 55	Controls 150 22 47 150 69 172 47 197 22	FDR's 24 39 8 24 47 63 8 32 39 Unad 1.00 1.9 (1 1.00	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)* justed OR (95%CI) 1.14 (0.65–1.9)	p <0.0001*
SNP HSP 90α Q488H SNP HSP 90α Q488H SNP HSP 90α Q488H SNP HSP 90α Q488H	Model Codominant Codominant Dominant Recessive Over-dominant C C G Allele C G Allele Allele Allele Allele Allele Allele	Genotype C/C C/G G/G C/C-G/G C/C-C/G G/G C/C-G/G C/G	Controls 150 22 47 150 69 172 47 197 22 LQTS 57 41 Cases 57 41 FDR's	FDR's 24 39 8 24 47 63 8 32 39 Unad 1.00 1.9 (1 1.00 1.9 (1 1.00 1.9 (1 1.00 1.9 (1 1.00 1.9 (1 1.00 1.9 (1 1.00 1.9 (1 1.00 1.9 (1 1.00 1.9 (1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)* justed OR (95%CI) 1.14 (0.65–1.9) justed OR (95%CI)	p <0.0001*
SNP HSP 90α Q488H SNP HSP 90α Q488H SNP HSP 90α Q488H SNP HSP 90α Q488H SNP HSP 90α Q488H	Model Codominant Codominant Dominant Recessive Over-dominant C G Allele C G Allele C G Allele C G Allele C G C G C G C G C G C C G C C C C C C	Genotype C/C C/G G/G C/C-C/G G/G C/C-C/G G/G C/C-G/G C/C-G/G J22 116 FDR's 87 55 Controls 322 322	Controls 150 22 47 150 69 172 47 197 22 47 197 22	FDR's 24 39 8 24 47 63 8 32 39 Unad 1.00 1.9 (1 Unad 1.00 1.9 (1 Unad 1.00 1.9 (1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Adjusted OR (95%CI) 1.00 11.77 (5.4–25.64)* 1.04 (0.36–3.02) 1.00 4.53 (2.29–8.96)* 1.00 0.42 (0.16–1.13) 1.00 11.66 (5.61–24.24)* justed OR (95%CI) 1.14 (0.65–1.9) Justed OR (95%CI)	p <0.0001*

*risk conferred at p ≤ 0.05. Abbreviations: CI, confidence interval; FDR, first degree relative; HSP, heat shock protein; LQTS, long QT syndrome; OR, odds ratio.

65.04 at $p \le 0.00001$ was obtained, indicating that the "CG" genotype carriers might have bad/poor prognosis in their subsequent generation due to segregation of the recessive alleles (Table 3).

Relative risk estimate of LQTS cases against controls revealed the "CG" genotype to show a 4-fold and 3-fold risk to LQTS under the codominant, dominant and over-dominant models of inheritance (odds ratio (OR) = 4.25, 95% CI: 1.69–10.68, p = 0.0055, OR: 2.88, 95% CI: 1.43–5.82, p = 0.0029 and OR: 3.30, 95% CI: 1.39–7.88, p = 0.0088 respectively) (Table 4). When the alleles were compared for their relative risk, it was found that the 'G' allele contributed a 2-foldrisk (OR: 1.9, 95% CI: 1.24–3.22, p =0.004) towards LQTS manifestation (Table 4).

When the samples were adjusted for age within sex subclass, it was found that the females harboring the "CG" and "GG" genotypes, a 9-fold and 3.4-fold risk (OR: 8.61, 95% CI: 2.54–29.24 and OR: 3.4, 95% CI: 1.09–10.63 respectively) indicating a poor prognosis in the females and influence of HSP90a Q488H polymorphism in a sex-specific manner (Table 5). As one can see, the heterozygous "CG" genotype is conferring heterozygote disadvantage in LQTS.

The results obtained for the relative risk estimates for LQTS cases against the FDRs were interesting. The "GG" genotype conferred 4.5-fold risk (OR: 4.54, 95% CI: 1.24–16.57, p = 0.015) towards LQTS manifestation under the recessive inheritance model, while the "CG" genotype conferred protection (OR: 0.31, 95% CI: 0.11–0.83, p = 0.018) under the over-dominant model of inheritance (Table 4). This clearly indicates that the LQTS cases harboring the "GG" genotype are at risk, while the "CG" genotype seems to confer protection in the FDRs against a bad prognosis. The above result is contradictory to the earlier obtained result in the present study. No significant variation were observed in the distribution of alleles upon comparison of the LQTS cases and FDRs. Similarly, no significant variations were observed in the genotype distribution upon adjusting the samples for age within sex subclass (Table 5).

The "CG" genotype in the FDRs, when compared to controls, showed a 12-fold and 5-fold risk (OR: 11.77, 95% CI: 5.4–25.64, $p \le 0.0001$, OR: 4.53, 95% CI: 2.29–8.96, $p \le 0.0001$ and OR: 11.66, 95% CI: 5.61–24.24, $p \le 0.0001$ respectively) towards LQTS manifestation under the codominant, dominant and over-dominant models of inheritance. Thus, it was concluded that the heterozygote genotype can confer risk (heterozygote disadvantage) to the individual harboring it and to the future generation inheriting the recessive alleles from the predecessor. When the alleles were compared for relative risk, the 'G' allele conferred a 2-fold risk (OR: 1.76, 95% CI: 1.16–2.67, p = 0.008) towards disease manifestation (Table 4).

When adjusted for age, the "CG" and "GG" genotypes showed 40-fold and 7-fold risk (OR: 39.43, 95% CI: 9.52–163.41 and OR: 7.03, 95% CI: 1.55–31.85) towards disease progression in the females, while the "CG" genotype showed a 6-fold risk (OR: 5.53, 95% CI: 2.05–14.93) towards disease manifestation in the males. Thus, the "CG" genotype appears to be crucial, with respect to poor prognosis in both the sexes (Table 5). Hence, FDRs harboring the risky "CG" genotype pose the hazard of passing on these alleles to their future generation, which may be deleterious.

In silico analysis

No visible structural changes were observed in the pre-mRNA secondary structures of the individual alleles of HSP90a Q488H polymorphism. But, a change in the entropy values suggests the 'G' allele-encoded structure (-236.11 kcal/mol) to be unstable compared to the 'C' allele-encoded structure (-237.51 kcal/mol), further strengthening the risk posed by the 'G' allele, as determined

					HSP	<i>90α</i> Q488H				
Sex		n = 266,	, adjusted by	/ age		<i>n</i> = 96, adjus	ted by age		n = 266, a	idjusted by age
	Genotype	Controls, n	LQTS, n	OR	FDRs, n	LQTS, n	OR	Controls	FDRs	OR
Female	SS	93	11	1.00	3	11	1.00	93	3	1.00
	g	10	6	8.61 (2.54–29.24)*	13	6	0.26 (0.05–1.44)	10	13	39.43 (9.52–163.41)*
	GG	22	8	3.4 (1.09–10.63)*	ъ	8	0.69 (0.10–4.67)	22	ъ	7.03 (1.55–31.85)*
Male	2	57	10	1.00	12	10	1.00	57	12	1.00
	CG	12	3	1.53 (0.34–7.01)	16	3	0.53 (0.10–2.75)	12	16	5.53 (2.05–14.93)*
	GG	25	9	1.33 (0.40–4.37)	0	9	I	25	0	
			-							

Table 5. HSP90a genotype distribution with respect to sex



Fig. 2. Structural changes and entropy of the HSP90α Gln488His polymorphism. Abbreviation: HSP, heat shock protein.

statistically in the present study (Fig. 2).

The addition of an extra transcription factor (HNF-3) binding site at 862–871 bases would lead to up-regulation of transcription, possibly through chromatin remodeling (Fig. 3a and 3b) (accessed on 26-08-2015).⁹ Since the polymorphism identified is a missense change leading to glutamine being replaced by histidine, there is a possibility of alteration in the secondary structure of HSP90. In order to identify the change, the protein was submitted to PSIPRED, an online tool for predicting secondary structure (Fig. 4a and 4b) (accessed on 26-08-2015).¹⁰ No change in the secondary structure was observed due to the substitution of glutamine by histidine, but changes in the functionality of HSP90 cannot be ruled out.

Discussion

Chaperones play a crucial role in many cellular processes, like promotion of the folding of nascent polypeptide chains, of protein translocation across membranes and of protein degradation.¹¹ Molecular chaperones assist in the folding of nascent polypeptides and prevent unproductive interactionsfrom being incorporated in the final structure. One such chaperone is a90-kDa HSP and, an abundant protein in eukaryotic cells, comprising 1–2% of the entire cellular protein makeup under nonstress conditions.⁵

The current study was based upon the intramolecular interactions existing between the N and the M domainsof HSP90 and the homodimeric interaction between itsMC domains (amino acids 401–732), a set of interactions that are essential for the functioning of HSP90.¹² HSP90 mediates its actions via the formation of discrete subcomplexes containing proteins and cochaperones that assist in protein folding and refolding during stress, protein transport and degradation processes.⁵ "The environmentally responsive molecular chaperone HSP90 assists the maturation of many key regulatory proteins (steroid hormone receptors, kinases such as vsrc, and transcription factors such as the heat-shock factor). An unexpected consequence of this essential biochemical function is that genetic variation can accumulate in genomes and can remain phenotypically silent until HSP 90 function is challenged."¹¹

HSP90 plays key roles in various developmental processes, influencing a vast variety of signaling cascades. Hence, when there is compromise in the functioning of HSP90 due to intrinsic (HSP90 inhibitors) and/or extrinsic (environmental stressors) factors, a plei-



Fig. 4. Secondary protein structure encoded by the C allele and G allele of *HSP90α* Q488H. Abbreviation: HSP, heat shock protein.

otropic effect ensues, which has led to the characterization of HSP90 as a 'capacitor for evolution'. HSP90's ability to stabilize significant portions of mutated proteins has earned it the description of being a 'genetic capacitor', which adds to the ever-increasing complication involved with the translation of genotype to phenotype.¹³

Jackson proposed a mechanism of action for HSP90,¹ where by its interaction with various other cochaperones and their synergistic action helps in folding and maturation of nascent steroid receptors. A similar mechanism can be hypothesized to facilitate the folding of complex channel proteins, like the hERG and CFTR. This was further supported by findings from the study by Ficker *et al.*,¹⁴ identifying the partnership between the two cytosolic chaperones, HSP70 and HSP90. Ficker *et al.*¹⁴ stated that the HSP70 participates in *de novo* protein folding by holding newly synthesized chains in a state competent for folding and HSP90 facilitates folding of these proteins into complex conformations, interacting dynamically with the immature core-glycosylated endoplasmic reticulum-resident form of hERG. These, thereby, form a transient complex that helps in the molding of the protein into its actual form.¹

In the present study, we screened a South Indian cohort for the Q488H missense mutation, which represents a critical mutation as its presence leads to the weakening of the intermolecular dimeric interaction of HSP90. The fact that Q488 is highly conserved in the HSP-90family, including yeast Hsp82, yeast Hsc82, human Grp94, HtpG and *Drosophila melanogaster* Trap1, indicates the vital role played by the amino acid in maintaining intermolecular interactions.¹⁵

Future research prospective

Since the cohort selected in the present study represents only a small proportion of the population, further confirmations of the demographics in the general population is of prime interest. The frequencies of the SNP studied also need further confirmationusing a larger population size. To understand the exact functional constraint the SNP produces, further studies are warranted. One way to study the functional effect could be the establishment of cardiac cell lines with mutant HSP90 and subsequent investigation of its effect on protein dynamics, or alternatively the protein itself can be isolated and sub-



Fig. 3. Transcription factors binding to the C allele and G allele of HSP90α Q488H. Abbreviation: HSP, heat shock protein.

Ali A. et al: HSP 90 and LQTS

jected to detailed analysis to understand its structural intricacies.

Conclusions

In the present study, the CG heterozygotes are at a disadvantage, indicating that the presence of a single G allele is sufficient to render HSP90 capable of folding the ion channel improperly in a dominant-negative fashion. In addition, the homozygous GG genotype conferred risk in the LQTS, when compared against the FDRs. Hence, the transmission of the recessive G allele to the future generation from the FDRs (carriers) indicates a bad prognosis (statistically proven when the FDRs were compared against the controls and after adjusting for age).

Hence, the CG genotype increases risk for LQTS, and the FDRs, especially females harboring the CG and GG genotypes, can pass on this disadvantage to their future generations. Thus, the dominant-negative interactions together with the carriers posing a threat to transmit the recessive allele to their future generations warrants carrier detection and/or prenatal diagnosis to prevent the recurrence of sudden cardiac death events in the future generations.

Acknowledgments

Financial aid from the Department of Biotechnology, New Delhi and the Maulana Azad National Fellowship Scheme, University Grants Commission, New Delhi, as well as the cooperation of all the participants of the study, is sincerely acknowledged.

Conflict of interest

The authors have no conflict of interests related to this publication.

Author contributions

Performance of experiments (AA), analysis of data (AA, SFQ), statistical analysis (AA), interpretation of data (AA, SFQ), manuscript writing (AA), critical revision (VA, TK, PN), technical support (NC, HR, MPJ, JS), study design (PN).

References

- Jackson SE. Hsp90: structure and function. Top Curr Chem 2013;328:155–240. doi:10.1007/128_2012_356.
- [2] Sreedhar AS, Kalmár E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004;562(1– 3):11–15. doi:10.1016/S0014-5793(04)00229-7.
- [3] genecards.org [internet]. Weizmann Institute of Science. Available from: http://www.genecards.org/cgi-bin/carddisp.pl?gene=HSP90A A1&keywords=HSP,90,alpha. [Accessed 25 August 2015].
- [4] Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991;19(19):5444. doi:10.1093/nar/19.19.5444.
- [5] Zagouri F, Sergentanis TN, Gazouli M, Tsigginou A, Dimitrakakis C, Papaspyrou I, et al. HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study. Mol Biol Rep 2012;39(12):10873–10879. doi:10.1007/s11033-012-1984-2.
- [6] Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006;22(15):1928– 1929. doi:10.1093/bioinformatics/btl268.
- [7] Social Science Statistics [internet]. Available from: http://www.socscistatistics.com/Default.aspx. [Accessed 25 August 2015].
- [8] Hofacker IL. Vienna RNA secondary structure server. Nucleic Acids Res 2003;31(13):3429–3431. doi:10.1093/nar/gkg599.
- [9] gene-regulation.com [internet]. Available from: http://gene-regulation.com/pub/programs/alibaba2/index.html. [Accessed 25 August 2015].
- [10] Buchan DW, Minneci F, Nugent TC, Bryson K, Jones DT. Scalable web services for the PSIPRED Protein Analysis Workbench. Nucleic Acids Res 2013;41(Issue W1):W349–W357. doi:10.1093/nar/gkt381.
- [11] Sangster TA, Lindquist S, Queitsch C. Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays 2004;26(4):348–362. doi:10.1002/bies.20020.
- [12] Chen B, Piel WH, Gui L, Bruford E, Monteiro A. The HSP90 family of genes in the human genome: Insights into their divergence and evolution. Genomics 2005;86(6):627–637. doi:10.1016/j.ygeno.2005.08.012.
- [13] Iwai C, Li P, Kurata Y, Hoshikawa Y, Morikawa K, Maharani N, et al. Hsp90 prevents interaction between CHIP and HERG proteins to facilitate maturation of wild-type and mutant HERG proteins. Cardiovasc Res 2013;100(3):520–528. doi:10.1093/cvr/cvt200.
- [14] Brown MA, Zhu L, Schmidt C, Tucker PW. Hsp90—from signal transduction to cell transformation. Biochem Biophys Res Commun 2007;363(2):241–246. doi:10.1016/j.bbrc.2007.08.054.
- [15] Kobayakawa T, Yamada S, Mizuno A, Ohara-Nemoto Y, Baba TT, Nemoto TK. Single nucleotide polymorphism that accompanies a missense mutation (Gln488His) impedes the dimerization of Hsp90. Protein J 2009;28(1):24–28. doi:10.1007/s10930-008-9160-1.